Sunday, September 25, 2016 11:55:21 AM
and clean financial resources-lenders are not willing to broker a deal because of Amarantus's current heinous default crisis under the notorious clutches of Magna
then there 'might be' an out right buyout offer in the making here for ESS
as what prospective owner would want to own part of something dirty, when they can own the whole of it clean
however, without Ph. 2 or Ph. 3 test trial results, what large BioPharma that specializes in engineered substitute skin would put down a substantial offer for part of something that has dirty financing and is yet unknown
only questions remaining are what is "Corporate" doing
and will it be beneficial for shareholders who have already lost literally 99.8% of their investment
the sad truth is that Amaranthus is negotiating from weakness - as opposed to strength
sad but true
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM